Last reviewed · How we verify

Lutein/zeaxanthin and DHA/EPA

National Eye Institute (NEI) · Phase 3 active Small molecule

Lutein/zeaxanthin and DHA/EPA is a Nutritional supplement combination Small molecule drug developed by National Eye Institute (NEI). It is currently in Phase 3 development for Age-related macular degeneration (AMD), intermediate to advanced stages.

Lutein, zeaxanthin, and omega-3 fatty acids (DHA/EPA) accumulate in the retina to protect against oxidative damage and support macular health.

Lutein, zeaxanthin, and omega-3 fatty acids (DHA/EPA) accumulate in the retina to protect against oxidative damage and support macular health. Used for Age-related macular degeneration (AMD), intermediate to advanced stages.

At a glance

Generic nameLutein/zeaxanthin and DHA/EPA
SponsorNational Eye Institute (NEI)
Drug classNutritional supplement combination
ModalitySmall molecule
Therapeutic areaOphthalmology
PhasePhase 3

Mechanism of action

Lutein and zeaxanthin are carotenoids that filter harmful blue light and act as antioxidants in the macula, while DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid) are omega-3 polyunsaturated fatty acids that support retinal cell membrane integrity and reduce inflammation. Together, these nutrients are hypothesized to slow the progression of age-related macular degeneration (AMD) by reducing oxidative stress and supporting photoreceptor function.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Lutein/zeaxanthin and DHA/EPA

What is Lutein/zeaxanthin and DHA/EPA?

Lutein/zeaxanthin and DHA/EPA is a Nutritional supplement combination drug developed by National Eye Institute (NEI), indicated for Age-related macular degeneration (AMD), intermediate to advanced stages.

How does Lutein/zeaxanthin and DHA/EPA work?

Lutein, zeaxanthin, and omega-3 fatty acids (DHA/EPA) accumulate in the retina to protect against oxidative damage and support macular health.

What is Lutein/zeaxanthin and DHA/EPA used for?

Lutein/zeaxanthin and DHA/EPA is indicated for Age-related macular degeneration (AMD), intermediate to advanced stages.

Who makes Lutein/zeaxanthin and DHA/EPA?

Lutein/zeaxanthin and DHA/EPA is developed by National Eye Institute (NEI) (see full National Eye Institute (NEI) pipeline at /company/national-eye-institute-nei).

What drug class is Lutein/zeaxanthin and DHA/EPA in?

Lutein/zeaxanthin and DHA/EPA belongs to the Nutritional supplement combination class. See all Nutritional supplement combination drugs at /class/nutritional-supplement-combination.

What development phase is Lutein/zeaxanthin and DHA/EPA in?

Lutein/zeaxanthin and DHA/EPA is in Phase 3.

What are the side effects of Lutein/zeaxanthin and DHA/EPA?

Common side effects of Lutein/zeaxanthin and DHA/EPA include Gastrointestinal upset, Fish-like aftertaste (from omega-3 components), Mild nausea.

Related